Insmed, Inc. (NASDAQ:INSM) Shares Purchased by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Insmed, Inc. by 3.6% in Q1, owning approximately 0.88% of the company valued at $122.27 million.
• Multiple analysts have issued positive ratings for Insmed, with UBS Group raising its price target to $133.00, reflecting strong market outlook.
• Insmed reported a loss of ($1.70) EPS in its most recent earnings report, missing estimates, but achieved 18.9% revenue growth year-over-year.

Charles Schwab Investment Management Inc. grew its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 3.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,602,655 shares of the biopharmaceutical company's stock after acquiring an additional 56,048 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.88% of Insmed worth $122,267,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Darwin Global Management Ltd. boosted its position in shares of Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Brown Advisory Inc. acquired a new position in shares of Insmed in the 4th quarter valued at about $45,773,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Insmed by 59.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company's stock valued at $113,748,000 after buying an additional 615,000 shares during the period. Capital International Investors lifted its holdings in shares of Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after buying an additional 593,206 shares during the period. Finally, Duquesne Family Office LLC increased its stake in shares of Insmed by 2,867.4% in the 4th quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company's stock valued at $40,973,000 after purchasing an additional 573,470 shares in the last quarter.

Insmed Stock Performance

Shares of INSM stock traded up $0.05 during mid-day trading on Friday, hitting $127.80. 3,528,446 shares of the stock were exchanged, compared to its average volume of 2,934,935. The stock's fifty day simple moving average is $103.62 and its two-hundred day simple moving average is $83.88. The stock has a market capitalization of $27.01 billion, a price-to-earnings ratio of -22.38 and a beta of 0.95. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $128.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%. The company had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. During the same period in the prior year, the business earned ($1.94) EPS. The business's quarterly revenue was up 18.9% compared to the same quarter last year. On average, analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on INSM. Wells Fargo & Company set a $140.00 price objective on Insmed and gave the stock an "overweight" rating in a research note on Tuesday. Stifel Nicolaus upped their price target on Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a research report on Thursday. Truist Financial upped their price target on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday. Morgan Stanley reiterated an "equal weight" rating and issued a $126.00 price objective on shares of Insmed in a report on Wednesday. Finally, Mizuho upped their price objective on Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $129.57.

Insider Buying and Selling

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the transaction, the insider owned 89,407 shares of the company's stock, valued at $8,352,401.94. This trade represents a 52.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO William Lewis sold 129,805 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the completion of the sale, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. The trade was a 35.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 525,716 shares of company stock valued at $49,665,671 over the last quarter. 3.00% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.